<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		N/A
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.		N/A
Provide accession number in repository OR		
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		N/A
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		N/A
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		N/A
in repository (where relevant) OR RRID		

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		N/A
Microbes: provide species and strain, unique accession number if available, and source		N/A

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Yes. The study was approved by the Ethics Committee of	
equivalent committee(s), provide reference number	the Beijing Tongren Hospital, which was provided in the	
for approval.	Data acquisition and preparation Section.	
Provide statement confirming informed consent	Yes. It was provided in the Data acquisition and	
obtained from study participants.	preparation Section.	
Report on age and sex for all study participants.	Yes. It was provided in the Tilt angle and decentration of	
	IOL in 3D space Section in Results Section.	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		N/A
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	, , , , , , , , , , , , , , , , , , , ,	N/A
by-step protocols are available.		,,,
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
done, or if they were not carried out.		
Sample size determination		
Randomisation		N/A
Blinding		N/A
Inclusion/exclusion criteria	Yes, it was provided in the Data acquisition and	
	preparation Section	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	res (indicate where provided, section/paragraph)	N/A
replicated in laboratory		IN/A
Define whether data describe technical or biological	Yes. Twelve subjects were randomly chosen for the	
replicates	evaluation of the repeatability and reliability of the	
	method, which was provided in the <i>Results</i> Section.	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Yes. The study was approved by the Ethics	
authority granting ethics approval (IRB or equivalent	Committee of the Beijing Tongren Hospital, which	
committee(s), provide reference number for	was provided in the Data acquisition and preparation	
approval.	Section.	
Studies involving experimental animals: State details		N/A
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		N/A
relevant permits obtained, provide details of		
authority approving study; if none were required, explain why.		
· · ·	V. C.	
Dual Use Research of Concern (DURC) If study is subject to dual use research of concern,	Yes (indicate where provided: section/paragraph)	n/a
state the authority granting approval and reference		N/A
number for the regulatory approval		

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Yes. This information was provided in the Tilt angle and	
excluded, and whether the criteria for exclusion were	decentration of IOL in 3D space Section.	
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Yes. This information was provided in the Statistical	
tests.	analysis Section.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		N/A
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession		N/A
number in repository or DOI or URL.		
If publicly available data are reused, provide		N/A
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		N/A
for replicating the main findings of the study:		
State whether the code or software is available.		N/A
If code is publicly available, provide accession		N/A
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of	Yes. This was provided in last paragraph in the	
discipline-specific guidelines, established and	Introduction Section.	
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	Yes. This was provided in the footnote in the	
ARRIVE) have been followed, and whether a checklist	Introduction Section.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/atm-20-4706